Compare Gold Fields Limited (GFI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs GSK plc — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.9× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and GSK plc for 93 Days on average.
| GFI | GSK | |
|---|---|---|
Market Cap | $31.87B | $91.88B |
Volume | 4,169,651 | 7,730,529 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $61.18 |
52-Week Low | $31.25 | $43.24 |
Typical Hold Time | 49 Days | 93 Days |
Enterprise Value | $32.47B | $111.88B |
Dividend Yield | 6% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal and mixed earnings history. The stock shows strong fundamentals with a P/E of 7.3, net income margin of 38.66%, and robust cash flow growth, while recent news highlights a rejected $27 billion takeover bid for Northern Star, creating investor uncertainty.
The outlook is balanced: valuation metrics and profitability support upside toward the $52.75 analyst target, but near-term risks include acquisition-related volatility and technical weakness. Investors should weigh high ROE and cash returns against execution risks from expansion efforts.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
